Discounted Cash Flow Rating

Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Bio-Rad Laboratories, Inc.Class A (BIO)

Laboratory Analytical Instruments

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

1000 ALFRED NOBEL DRIVE
HERCULES, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/29/1980

Market Cap

9,099,345,987

Shares Outstanding

24,060,000

Weighted SO

29,145,170

Total Employees

N/A

Upcoming Earnings

10/24/2024

Similar Tickers

TNDM --.--%

DXCM --.--%

INSP --.--%

SWAV --.--%

PEN --.--%

CNMD --.--%

BRKR --.--%

ZBH --.--%

GKOS --.--%

Beta

0.9300

Last Div

0.0000

Range

261.59-406.44

Chg

0.1150

Avg Vol

256920

Mkt Cap

9099345987

Exch

NYSE

Country

US

Phone

510 724 7000

DCF Diff

163.4837

DCF

160.3413

Div Yield

0.0000

P/S

3.5508

EV Multiple

18.4630

P/FV

1.3644

Div Yield %

0.0000

P/E

-6.9774

PEG

-1.7295

Payout

-64.4648

Current Ratio

6.2762

Quick Ratio

4.6258

Cash Ratio

0.8364

DSO

64.8507

DIO

248.8454

Op Cycle

313.6961

DPO

39.2276

CCC

274.4685

Gross Margin

0.5400

Op Margin

0.1331

Pretax Margin

-0.6750

Net Margin

-0.5173

Eff Tax Rate

0.2336

ROA

-0.1368

ROE

-0.1607

ROCE

0.0371

NI/EBT

0.7664

EBT/EBIT

-5.0718

EBIT/Rev

0.1331

Debt Ratio

0.1272

D/E

0.1818

LT Debt/Cap

0.1494

Total Debt/Cap

0.1538

Int Coverage

6.9177

CF/Debt

0.2804

Equity Multi

1.4292

Rec Turnover

5.6283

Pay Turnover

9.3047

Inv Turnover

1.4668

FA Turnover

3.5829

Asset Turnover

0.2645

OCF/Share

12.1704

FCF/Share

6.2267

Cash/Share

57.1245

OCF/Sales

0.1349

FCF/OCF

0.5116

CF Coverage

0.2804

ST Coverage

8.2289

CapEx Coverage

2.0476

Div&CapEx Cov

0.0040

P/BV

1.3644

P/B

1.3644

P/S

3.5508

P/E

-6.9774

P/FCF

51.4651

P/OCF

26.7645

P/CF

26.7645

PEG

-1.7295

P/S

3.5508

EV Multiple

18.4630

P/FV

1.3644

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 12, 22:17 SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma GlobeNewswire Inc. Jun 10, 22:39 Zenas BioPharma, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 16, 2025 Deadline to file Lead Plaintiff Motion GlobeNewswire Inc. Jun 10, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and Avis Budget and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 03, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and BigBear and Encourages Investors to Contact the Firm GlobeNewswire Inc. May 29, 23:16 ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO GlobeNewswire Inc. May 18, 23:30 Antibody and Protein Labeling Kits Market Outlook, Trends, Growth and Opportunities | Exactitude Consultancy GlobeNewswire Inc. May 17, 16:00 ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO GlobeNewswire Inc. May 15, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and BigBear and Encourages Investors to Contact the Firm GlobeNewswire Inc. May 09, 23:34 Cohen Milstein Continues Lead Plaintiff Search for Zenas BioPharma (ZBIO) Securities Fraud Class Action Following Post-IPO Stock Decline GlobeNewswire Inc. May 06, 00:06 ZBIO Stock Notice: Zenas BioPharma, Inc. Stockholders are Encouraged to Contact Shareholder Rights Law Firm Robbins LLP for Information About the ZBIO Class Action GlobeNewswire Inc. Apr 29, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, and Zenas BioPharma and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 18, 00:00 Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. (ZBIO) GlobeNewswire Inc. Apr 16, 23:00 ZBIO INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO GlobeNewswire Inc. Apr 16, 22:41 ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead the Zenas BioPharma Class Action Lawsuit GlobeNewswire Inc. Apr 04, 19:20 Bioprocess Optimization and Digital Bio-manufacturing Market Forecast 2029 GlobeNewswire Inc. Apr 03, 22:30 Texas Capital Bancshares, Inc. Announces Date for Q1 2025 Operating Results GlobeNewswire Inc. Mar 27, 14:00 Biopesticides Market to Reach USD 25.82 Billion by 2032 | SNS Insider GlobeNewswire Inc. Mar 21, 20:00 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Mar 01, 21:11 BIOA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA GlobeNewswire Inc. Mar 01, 21:11 BIOA ???????????????? ROSEN ????? 10 ???? BioAge Labs, Inc. ????? BIOA ??????????????? 3 ? 10 ??????

Revenue Product Segmentation